Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high‐penetrance genes

We assessed the association between breast cancer (BC) and colorectal cancer (CRC) from referral pattern to the Regional Genetics Service including molecular analysis. Hospital computer records and/or department referral books were used to identify cases referred to the Regional Genetic Service during a 16‐year period (1990–2005 inclusive). All files were reviewed along with associated demographic data, risk assessments, referral details and results from mutation testing. Families were assessed for hereditary breast and colorectal cancer (HBCC) criteria, and all families with eligible individuals were tested for the 1100delC mutation in CHEK2. A total of 8612 families were identified. One hundred and sixteen of 1631 (7.5%) families with a primary referral for CRC fulfilled the criteria for HBCC, whereas only 68/6981 (1%) BC referrals fulfilled these criteria. Blood samples were obtained from 113 individuals from 83/184 families. Only 1/113 (1%) has screened positive for the CHEK2 mutation, whereas 14 (17%) families segregate BRCA1/2 mutations and at least 7 (8.5%) carry MLH1/MSH2 mutations. HBCC syndrome, if it exists as a separate entity, is not likely to be due to CHEK2 mutations. Many families are explicable by existing high‐penetrance genes, and further work is necessary to elucidate whether the remainder is due to chance or as yet undiscovered genes.

[1]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[2]  R. Hofstra,et al.  Colorectal cancer and the CHEK2 1100delC mutation , 2005, Genes, chromosomes & cancer.

[3]  J. Satagopan,et al.  Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. , 2004, Journal of the National Cancer Institute.

[4]  Ronit Almog,et al.  BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. , 2004, Journal of the National Cancer Institute.

[5]  H. Nakagawa,et al.  Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques , 2003, Human mutation.

[6]  J. Klijn,et al.  The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. , 2003, American journal of human genetics.

[7]  Nazneen Rahman,et al.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. , 2003, American journal of human genetics.

[8]  R. Tollenaar,et al.  Correspondence re: A. Müller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res., 62: 1014-1019, 2002. , 2003, Cancer research.

[9]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[10]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[11]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[12]  J. Palazzo,et al.  Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. , 2002, Cancer research.

[13]  P. Babb,et al.  Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  H. Morreau,et al.  Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? , 2001, American journal of human genetics.

[15]  D. Evans,et al.  Re: Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. , 2001, Journal of the National Cancer Institute.

[16]  C. Newschaffer,et al.  Risk of colorectal cancer after breast cancer , 2001, The Lancet.

[17]  J. Peto,et al.  High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.

[18]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[19]  H. Lynch,et al.  Colorectal cancer in hereditary breast cancer kindreds , 1999, Diseases of the colon and rectum.

[20]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[21]  D. Evans,et al.  The accuracy of diagnoses as reported in families with cancer: a retrospective study , 1999, Journal of medical genetics.

[22]  T. Smyrk,et al.  An update on Lynch syndrome. , 1998, Current opinion in oncology.

[23]  M. McCredie,et al.  Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  W. Foulkes,et al.  Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. , 1996, Journal of medical genetics.

[25]  K. Kinzler,et al.  Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients , 1996, Nature Medicine.

[26]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[27]  R. Sandler,et al.  Are women with breast cancer more likely to develop colorectal cancer? Critical review and meta-analysis. , 1994, Journal of clinical gastroenterology.

[28]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[29]  G. Sledge,et al.  Colonic adenomas in asymptomatic women with a history of breast cancer. , 1993, The American journal of gastroenterology.

[30]  D. Evans,et al.  Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry , 1993, Cancer.

[31]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[32]  J. Benítez,et al.  The breast cancer low‐penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population , 2004, International journal of cancer.

[33]  J. Godino,et al.  The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families , 2004, Familial Cancer.

[34]  D. Easton,et al.  Cancer incidence in BRCA1 mutation carriers , 2003 .

[35]  R. Scott,et al.  Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. , 2001, American journal of human genetics.

[36]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[37]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[38]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.